Carson Advisory Inc. Purchases New Position in Eli Lilly and Company (NYSE:LLY)

Carson Advisory Inc. purchased a new stake in shares of Eli Lilly and Company (NYSE:LLYGet Rating) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,130 shares of the company’s stock, valued at approximately $312,000.

A number of other hedge funds also recently made changes to their positions in LLY. Morgan Stanley increased its position in shares of Eli Lilly and by 8.2% in the second quarter. Morgan Stanley now owns 3,822,819 shares of the company’s stock valued at $877,414,000 after buying an additional 289,490 shares in the last quarter. Segall Bryant & Hamill LLC increased its position in shares of Eli Lilly and by 4.9% in the third quarter. Segall Bryant & Hamill LLC now owns 14,051 shares of the company’s stock valued at $3,247,000 after buying an additional 655 shares in the last quarter. Financial Advocates Investment Management increased its position in shares of Eli Lilly and by 2.4% in the third quarter. Financial Advocates Investment Management now owns 4,504 shares of the company’s stock valued at $1,040,000 after buying an additional 107 shares in the last quarter. Mather Group LLC. increased its position in shares of Eli Lilly and by 8.5% in the third quarter. Mather Group LLC. now owns 4,936 shares of the company’s stock valued at $1,140,000 after buying an additional 385 shares in the last quarter. Finally, Deutsche Bank AG increased its position in shares of Eli Lilly and by 18.7% during the third quarter. Deutsche Bank AG now owns 3,064,548 shares of the company’s stock worth $708,065,000 after purchasing an additional 483,698 shares in the last quarter. Institutional investors own 82.16% of the company’s stock.

LLY traded down $5.14 during mid-day trading on Friday, hitting $292.13. 3,910,872 shares of the stock were exchanged, compared to its average volume of 2,576,194. The firm’s fifty day moving average is $281.25 and its two-hundred day moving average is $262.96. Eli Lilly and Company has a 1-year low of $181.19 and a 1-year high of $314.00. The company has a current ratio of 1.23, a quick ratio of 0.97 and a debt-to-equity ratio of 1.68. The company has a market cap of $278.21 billion, a PE ratio of 43.28, a PEG ratio of 2.14 and a beta of 0.43.

Eli Lilly and (NYSE:LLYGet Rating) last posted its earnings results on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.30. Eli Lilly and had a return on equity of 96.36% and a net margin of 19.71%. The firm had revenue of $7.81 billion for the quarter, compared to analyst estimates of $7.29 billion. During the same quarter in the prior year, the company earned $1.87 EPS. Eli Lilly and’s revenue was up 14.8% on a year-over-year basis. As a group, research analysts anticipate that Eli Lilly and Company will post 8.24 earnings per share for the current year.

In other Eli Lilly and news, SVP Ilya Yuffa sold 1,000 shares of the company’s stock in a transaction dated Tuesday, February 15th. The stock was sold at an average price of $237.45, for a total transaction of $237,450.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 139,045 shares of the company’s stock in a transaction dated Friday, April 8th. The stock was sold at an average price of $310.79, for a total value of $43,213,795.55. Following the sale, the insider now owns 105,573,810 shares in the company, valued at approximately $32,811,284,409.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,088,551 shares of company stock worth $307,943,730. 0.12% of the stock is owned by corporate insiders.

Several analysts recently commented on the company. Bank of America boosted their price target on Eli Lilly and from $300.00 to $315.00 in a research report on Thursday, March 17th. Sanford C. Bernstein boosted their price target on Eli Lilly and from $250.00 to $300.00 and gave the stock a “market perform” rating in a research report on Monday, January 3rd. Wells Fargo & Company boosted their price target on Eli Lilly and from $280.00 to $305.00 in a research report on Friday. Mizuho dropped their price target on Eli Lilly and from $302.00 to $293.00 and set a “buy” rating for the company in a research report on Friday, February 4th. Finally, The Goldman Sachs Group boosted their price objective on Eli Lilly and from $234.00 to $264.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $299.06.

Eli Lilly and Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.